Genomic Vision Société Anonyme (ENXTPA:GV) announced that it has entered into financing agreement with returning investor, Winance Investment, LLC for private placement of convertible notes with equity warrants for an aggregate gross proceeds of €12,000,000 on June 11, 2020. The notes are convertible into common shares of the company. The notes will have a nominal value of €1,000 each and will be subscribed at par. The notes will bear no interest and mature in 12 months from the date of issuance. The notes have to be reimbursed should certain defaults occur with a penalty equal to 5% of nominal value. The company may issue bonds in 12 tranches of €1,000,000 each over a period of 24 months. The warrants will give the investor the right to subscribe to one ordinary share for every four share subscription warrants. The warrants can be exercisable for a period of 5 years from the date of issuance. The notes have to be subscribed within 10 days of the boards decision. The transaction is subject to approval from shareholders of the company.